GSK's chronic hepatitis B treatment meets main goal in key studies

GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...

GSK's chronic hepatitis B therapy shows promise in key studies, analysts await full data

GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepat…

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, ...

MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus

MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic ...
Yahoo

Drugs approved a decade ago can cure hepatitis C, but most infected Americans still can’t get them, study shows

For a decade now, the world has had highly effective medications for hepatitis C infections. In the United States, they’ve mostly been sitting on the shelf, according to a new study. These drugs, ...
BioSpace

GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
Everyday Health

People Who’ve Injected Drugs Deserve Hep C Treatment, Too

U ntil recently, most people diagnosed with hepatitis C were baby boomers, many of whom got the infection via a blood transfusion. As of 2024, hepatitis C is mostly spread via needles, syringes, and ...
STAT

We have a cure for hepatitis C — so why aren’t more people getting treatment?

In 2005, Nick Voyles was diagnosed with hepatitis C after being released from five years of incarceration. A nurse told him he had only six months to live. He was prescribed a drug cocktail, a ...